Overview Dividends

(CYTK) Cytokinetics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US23282W6057

Cardiac Activator, Skeletal Activator, Cardiac Inhibitor

CYTK EPS (Earnings per Share)

EPS Growth (3Y CAGR): -17.08%
EPS Trend (3Y Correlation): 23.7%

CYTK Revenue

Revenue Growth (3Y CAGR): -0.39%
Revenue Trend (3Y Correlation): 33.1%

Risk via 10d forecast
Volatility	55.7%
Value at Risk 5%th	77.4%

Reward
Sharpe Ratio	0.47
Alpha Jensen	2.00

Character
Hurst Exponent	0.613
Beta	0.592

Drawdowns 3y
Max DD	72.39%
Mean DD	39.77%

Description: CYTK Cytokinetics November 05, 2025

Cytokinetics Inc. (NASDAQ:CYTK) is a late-stage biotech that designs small-molecule muscle activators and inhibitors to treat serious U.S. diseases. Its lead programs are omecamtiv mecarbil (a cardiac myosin activator in Phase III for heart failure), CK-089 (a fast skeletal muscle troponin activator in Phase I), CK-586 (a cardiac myosin inhibitor in Phase II), and aficamten (an oral cardiac myosin inhibitor in Phase III for hypertrophic cardiomyopathy). The company also holds a strategic alliance with Ji Xing Pharmaceuticals for aficamten’s development and commercialization in Japan.

As of the latest quarterly filing, Cytokinetics reported a cash runway of roughly $250 million, supporting its R&D spend of about $120 million year-to-date. The Phase III GALACTIC-HF trial for omecamtiv mecarbil is slated for data readout in Q2 2026, while aficamten’s Phase III trial (EXPLORER-HCM) expects results by early 2025. The firm’s market capitalization hovers near $1.3 billion, reflecting investor weighting of these late-stage assets.

The cardiovascular biotech sector is being driven by an aging U.S. population and the expanding prevalence of heart failure, projected to affect over 6 million Americans by 2030. Concurrently, the biotech funding environment remains favorable, with venture capital allocating roughly $30 billion annually to early-stage therapeutics, but late-stage companies like CYTK must demonstrate clear regulatory milestones to sustain valuation.

For a deeper, data-rich perspective on CYTK’s risk-adjusted upside, you may find it worthwhile to explore the analyst tools on ValueRay.

CYTK Stock Overview

Market Cap in USD	7,355m
Sub-Industry	Biotechnology
IPO / Inception	2004-04-29
Return 12m vs S&P 500	2.79%
Analyst Rating	4.29 of 5

CYTK Dividends

Currently no dividends paid

CYTK Growth Ratios

CAGR	17.99%
CAGR/Max DD Calmar Ratio	0.25
CAGR/Mean DD Pain Ratio	0.45
Current Volume	2313.7k
Average Volume	1891k

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-751.9m TTM) > 0 and > 6% of Revenue (6% = 5.23m TTM)

FCFTA -0.32 (>2.0%) and ΔFCFTA -3.22pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 957.7% (prev 28.2k%; Δ -27.3kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.30 (>3.0%) and CFO -432.9m > Net Income -751.9m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 6.88 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (120.0m) change vs 12m ago 1.95% (target <= -2.0% for YES)

Gross Margin -127.5% (prev -10.2k%; Δ 10.0kpp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 6.07% (prev 0.22%; Δ 5.85pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -6.82 (EBITDA TTM -646.2m / Interest Expense TTM 96.1m) >= 6 (WARN >= 3)

Altman Z'' -8.52

(A) 0.58 = (Total Current Assets 977.3m - Total Current Liabilities 142.1m) / Total Assets 1.44b

(B) -2.30 = Retained Earnings (Balance) -3.30b / Total Assets 1.44b

warn (B) unusual magnitude: -2.30 — check mapping/units

(D) -1.69 = Book Value of Equity -3.30b / Total Liabilities 1.96b

Total Rating: -8.52 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 43.11

1. Piotroski 0.0pt = -5.0

2. FCF Yield -6.10% = -3.05

3. FCF Margin data missing

4. Debt/Equity -1.99 = -2.50

5. Debt/Ebitda -1.26 = -2.50

7. RoE 232.9% = 2.50

8. Rev. Trend 33.07% = 2.48

9. EPS Trend 23.71% = 1.19

What is the price of CYTK shares?

As of November 14, 2025, the stock is trading at USD 65.52 with a total of 2,313,700 shares traded.
Over the past week, the price has changed by +8.66%, over one month by +9.95%, over three months by +77.66% and over the past year by +17.08%.

Is Cytokinetics a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Cytokinetics (NASDAQ:CYTK) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 43.11 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CYTK is around 64.38 USD . This means that CYTK is currently overvalued and has a potential downside of -1.74%.

Is CYTK a buy, sell or hold?

Cytokinetics has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy CYTK.

Strong Buy: 9
Buy: 9
Hold: 3
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the CYTK price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	77.6	18.5%
Analysts Target Price	77.6	18.5%
ValueRay Target Price	71.1	8.5%

CYTK Fundamental Data Overview November 10, 2025

Market Cap USD = 7.36b (7.36b USD * 1.0 USD.USD)
P/S = 84.3409
P/B = 60.3093
P/EG = -0.42
Beta = 0.592
Revenue TTM = 87.2m USD
EBIT TTM = -655.8m USD
EBITDA TTM = -646.2m USD
Long Term Debt = 645.6m USD (from longTermDebt, last fiscal year)
Short Term Debt = 37.9m USD (from shortTermDebt, last quarter)
Debt = 1.04b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 812.6m USD (from netDebt column, last quarter)
Enterprise Value = 7.43b USD (7.36b + Debt 1.04b - CCE 962.5m)
Interest Coverage Ratio = -6.82 (Ebit TTM -655.8m / Interest Expense TTM 96.1m)
FCF Yield = -6.10% (FCF TTM -453.4m / Enterprise Value 7.43b)
FCF Margin = -519.9% (FCF TTM -453.4m / Revenue TTM 87.2m)
Net Margin = -862.2% (Net Income TTM -751.9m / Revenue TTM 87.2m)
Gross Margin = -127.5% ((Revenue TTM 87.2m - Cost of Revenue TTM 198.4m) / Revenue TTM)
Gross Margin QoQ = -38.38% (prev 96.58%)
Tobins Q-Ratio = 5.17 (Enterprise Value 7.43b / Total Assets 1.44b)
Interest Expense / Debt = 2.54% (Interest Expense 26.3m / Debt 1.04b)
Taxrate = 21.0% (US default 21%)
NOPAT = -518.1m (EBIT -655.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.88 (Total Current Assets 977.3m / Total Current Liabilities 142.1m)
Debt / Equity = -1.99 (negative equity) (Debt 1.04b / totalStockholderEquity, last quarter -521.1m)
Debt / EBITDA = -1.26 (negative EBITDA) (Net Debt 812.6m / EBITDA -646.2m)
Debt / FCF = -1.79 (negative FCF - burning cash) (Net Debt 812.6m / FCF TTM -453.4m)
Total Stockholder Equity = -322.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -52.34% (Net Income -751.9m / Total Assets 1.44b)
RoE = 232.9% (negative equity) (Net Income TTM -751.9m / Total Stockholder Equity -322.9m)
RoCE = -203.2% (out of range, set to none) (EBIT -655.8m / Capital Employed (Equity -322.9m + L.T.Debt 645.6m))
RoIC = -122.2% (out of range, set to none) (NOPAT -518.1m / Invested Capital 424.1m)
WACC = 7.43% (E(7.36b)/V(8.39b) * Re(8.20%) + D(1.04b)/V(8.39b) * Rd(2.54%) * (1-Tc(0.21)))
Discount Rate = 8.20% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.05%
Fair Price DCF = unknown (Cash Flow -453.4m)
EPS Correlation: 23.71 | EPS CAGR: -17.08% | SUE: 0.11 | # QB: 0
Revenue Correlation: 33.07 | Revenue CAGR: -0.39% | SUE: -0.18 | # QB: 0

Additional Sources for CYTK Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle